Edition:
United States

Abeona Therapeutics Inc (ABEO.OQ)

ABEO.OQ on NASDAQ Stock Exchange Capital Market

13.45USD
23 Feb 2018
Change (% chg)

$0.10 (+0.75%)
Prev Close
$13.35
Open
$13.35
Day's High
$13.85
Day's Low
$12.80
Volume
150,880
Avg. Vol
260,870
52-wk High
$22.70
52-wk Low
$4.55

Latest Key Developments (Source: Significant Developments)

Abeona Receives FDA Orphan Drug Status For Gene Therapy To Treat Rare Disease In Newborns
Monday, 12 Feb 2018 08:45am EST 

Feb 12 (Reuters) - Abeona Therapeutics Inc ::ABEONA THERAPEUTICS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR ABO-202 GENE THERAPY PROGRAM IN INFANTILE BATTEN DISEASE.ABEONA THERAPEUTICS INC - ABO-202 IS ANTICIPATED TO ENTER CLINICAL TRIALS IN 2018.  Full Article

Abeona Receives FDA Regenerative Medicine Advanced Therapy Status For Experimental Gene Therapy For Rare Skin Disorder
Monday, 29 Jan 2018 08:45am EST 

Jan 29 (Reuters) - Abeona Therapeutics Inc ::ABEONA RECEIVES FDA REGENERATIVE MEDICINE ADVANCED THERAPY DESIGNATION FOR EB-101 GENE THERAPY IN EPIDERMOLYSIS BULLOSA.ABEONA THERAPEUTICS - CONTINUES TO ENGAGE FDA ON ITS PIVOTAL PHASE 3 CLINICAL TRIAL DESIGN, AND WILL PROVIDE AN UPDATE ON RMAT PROGRAM IN COMING MONTHS.  Full Article

Abeona Q3 loss per share $0.13
Wednesday, 15 Nov 2017 08:25am EST 

Nov 15 (Reuters) - Abeona Therapeutics Inc :Abeona reports third quarter 2017 financial results and recent business highlights.Q3 loss per share $0.13.Q3 revenue $219,000 versus I/B/E/S view $220,000.Q3 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S.  Full Article

Abeona Therapeutics announces public offering of common stock
Monday, 16 Oct 2017 04:01pm EDT 

Oct 17 (Reuters) - Abeona Therapeutics Inc :Abeona Therapeutics announces public offering of common stock.  Full Article

Abeona Therapeutics to receive $13.85 mln of grants for development of Sanfilippo gene therapy programs​
Monday, 16 Oct 2017 08:26am EDT 

Oct 16 (Reuters) - Abeona Therapeutics Inc :Abeona Therapeutics Inc - ‍nine global foundations collaborate to grant $13.85 million for continued advancement of lead Sanfilippo gene therapy programs​.  Full Article

Abeona Therapeutics enrolls first two patients in phase 1/2 clinical trial in MPS IIIA
Wednesday, 11 Oct 2017 08:19am EDT 

Oct 11 (Reuters) - Abeona Therapeutics Inc : :Abeona Therapeutics enrolls first two patients in pivotal expansion of phase 1/2 clinical trial in MPS IIIA.Says to ‍report additional clinical data in ABO-102 global trial later this year​.  Full Article

Abeona Therapeutics and Brammer Bio announce collaboration for commercial translation of ABO-102
Thursday, 28 Sep 2017 08:32am EDT 

Sept 28 (Reuters) - Abeona Therapeutics Inc :Abeona Therapeutics and Brammer Bio announce collaboration for commercial translation of ABO-102.Abeona Therapeutics Inc - ‍strategic alignment with Brammer Bio for commercial AAV process development, scale up and assay validation​.  Full Article

Abeona Therapeutics receives FDA breakthrough therapy designation for EB-101
Tuesday, 29 Aug 2017 09:05am EDT 

Aug 29 (Reuters) - Abeona Therapeutics Inc :Abeona Therapeutics receives FDA breakthrough therapy designation for EB-101 autologous cell therapy in Epidermolysis Bullosa.Abeona Therapeutics Inc - company continues to engage FDA on final phase 3 clinical trial design, planned to commence early 2018.  Full Article

Abeona Therapeutics expands gene therapy clinical trials in Sanfilippo Syndrome Type A
Wednesday, 16 Aug 2017 09:25am EDT 

Aug 16 (Reuters) - Abeona Therapeutics Inc :Abeona Therapeutics announces pivotal expansion of ABO-102 gene therapy clinical trials in Sanfilippo Syndrome Type A.Abeona Therapeutics Inc - ‍planned expansion will enroll an additional eight to ten mps IIIA subjects​.Abeona Therapeutics Inc - ‍total enrollment of fourteen to sixteen subjects to be completed by 1Q2018​.  Full Article

Abeona Therapeutics receives guidance from FDA
Tuesday, 18 Jul 2017 08:05am EDT 

July 18 (Reuters) - Abeona Therapeutics Inc ::Abeona Therapeutics receives guidance from FDA to commence pivotal phase 3 for EB-101 gene therapy for patients with epidermolysis bullosa.Abeona Therapeutics Inc - ‍pivotal phase 3 clinical trial is planned to commence in early 2018​.Says pivotal phase 3 clinical trial is planned to commence in early 2018.Abeona Therapeutics Inc - ‍continues to engage FDA on final phase 3 clinical trial design, planned to commence early 2018​.Abeona Therapeutics Inc - continues to engage FDA on final phase 3 clinical trial design, planned to commence early 2018.  Full Article

BRIEF-Abeona Receives FDA Orphan Drug Status For Gene Therapy To Treat Rare Disease In Newborns

* ABEONA THERAPEUTICS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR ABO-202 GENE THERAPY PROGRAM IN INFANTILE BATTEN DISEASE